Phenotypic and genetic characterization of enteropathogenic Escherichia coli (EPEC) and entero-aggregative E. coli (EAEC) from diarrhoeal and non-diarrhoeal children in Libya

Comparative Immunology, Microbiology and Infectious Diseases
M A DowB Nagy

Abstract

A total of 50 Escherichia coli strains isolated in a Libyan hospital (20 from children with diarrhoea and 30 from healthy children) were investigated for their pathotypes and virulence traits. Altogether nine eae-positive (enteropathogenic E. coli, EPEC) and nine aggR-positive (entero-aggregative E. coli, EAEC) strains were identified. Significantly (P=0.001) more EPEC strains were identified from diarrhoeal patients (n=8) than from healthy controls (n=1), while six EAEC strains were identified from diarrhoeal and three from healthy children. Typical (eae(+), EAF(+), bfp(+)) EPEC strains (n=6) belonged to classical EPEC serogroups O55, O114, O127 and showed localized adherence on Hela cells. EAEC strains revealed genetic heterogeneity but uniformly adhered to HeLa cultures in an entero-aggregative adherence pattern. Antibiotic resistance frequently, characterized the strains. Sixty-eight percentage of the strains were resistant against at least one antibiotic and 30% harbored a class 1 integron independently of their clinical background. This is the first report from North Africa demonstrating the significance of EPEC and EAEC.

References

Jan 1, 1995·Antimicrobial Agents and Chemotherapy·C LévesqueP H Roy
Feb 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·T K McDanielJ B Kaper
Apr 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·S J SavarinoP Guerry
Mar 18, 2000·Infection and Immunity·J M KlapprothM S Donnenberg
Feb 24, 2001·Nature·N T PernaF R Blattner
May 9, 2002·Emerging Infectious Diseases·Luiz R TrabulsiTânia A Tardelli Gomes
Jun 7, 2003·Journal of Clinical Microbiology·Werner L PabstDavid Nadal
Feb 24, 2004·Infection and Immunity·Hayley J NewtonElizabeth L Hartland
Mar 9, 2004·Journal of Clinical Microbiology·Andresa ZamboniIsabel C A Scaletsky
Mar 26, 2004·Nature Reviews. Microbiology·James B KaperHarry L Mobley
May 14, 2004·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Amy GassamaMarie-Cecile Ploy
Dec 8, 2004·Journal of Clinical Microbiology·Hind I ShaheenStephen J Savarino

❮ Previous
Next ❯

Citations

May 1, 2012·Canadian Journal of Microbiology·S NajibiM Tajbakhsh
Apr 20, 2013·Bulletin of the World Health Organization·Gordon C McCordPrabhjot Singh
Jun 3, 2011·The American Journal of Tropical Medicine and Hygiene·Amal RahoumaKhalifa Sifaw Ghenghesh
May 5, 2012·The American Journal of Tropical Medicine and Hygiene·Mostafa Mohamed M AliKhalifa Sifaw Ghenghesh
Jun 4, 2014·Current Tropical Medicine Reports·Teresa Estrada-GarciaMussaret B Zaidi
Dec 4, 2012·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Bita BakhshiMohammad R Pourshafie
Oct 5, 2013·Clinical Microbiology Reviews·Matthew A CroxenB Brett Finlay

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antibodies: Agglutination

Antibody-mediated agglutination is the clumping of cells in the presence of antibody, which binds multiple cells together. This enhances the clearance of pathogens. Find the latest research on antibody-mediated agglutination here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.